Voriconazole

Drug Profile

Voriconazole

Alternative Names: Betadex sulfobutyl ether sodium enabled IV voriconazole; Captisol-enabled IV voraconazole; SBECD enabled IV voriconazole; Sulphobutly ether beta cyclodextrin enabled IV voriconazole; UK-109496; Vfend

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antifungals; Pyrimidines; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aspergillosis; Candidiasis; Fusariosis; Mycoses

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 Aug 2015 No development reported - Phase-III for Candidiasis (In adolescents, In children) in Mexico, Czech Republic, Hong Kong, Hungary, Philippines, Poland, Slovakia, China (PO and IV)
  • 30 Sep 2013 First generic equivalent of Vfend® (PO, solution) available in USA for Mycoses
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top